Administration
For all antiarrhythmic drugs, intravenous administration necessitates careful monitoring of the patient for adverse events. For many agents, the rate of intravenous drug delivery can be critical for both therapeutic and undesirable effects. For example, successful therapy with adenosine requires very rapid administration, preferably through a central line, to achieve the desired therapeutic effect prior to drug elimination from the circulation. However if a dose of intravenous lidocaine is administered too rapidly, severe neurologic side effects including seizures can result. Similarly, preclinical data suggest that the incidence of excessive QT prolongation and associated polymorphic ventricular tachycardia (Torsades de Pointes) with QT-prolonging drugs may be increased if the drug is given rapidly. Even with current dosing regimens, the incidence of Torsades de Pointes with ibutilide is on the order of 4-8%. Another problem encountered not infrequently during drug infusion is acute hypotension, as can occur with procainamide, calcium channel blockers such as verapamil and diltiazem, β-adrenergic receptor blockers such as esmolol, and amiodarone. This problem can usually be eliminated by reducing the rate of drug administration, or if necessary drug discontinuation. A more delayed hypotensive response can be seen with intravenous bretylium due to inhibition of norepinephrine re-uptake at presynaptic neurons. This adverse effect is typically not related to the drug infusion rate and is best treated with intravenous fluids. Unfortunately, the occurrence of such hypotension with bretylium can change recurrent, sustained ventricular tachycardia which was previously welltolerated into an arrhythmia that is now associated with hemodynamic collapse. In addition to infusion rate, the site of drug delivery can be equally important. Intravenous amiodarone should be administered through a central line to avoid phlebitis, which can be severe.
During oral administration, a variety of factors can affect drug disposition. Bioavailability defines the amount of the drug which reaches the systemic circulation after oral administration compared to the amount available following intravenous delivery. For amiodarone, oral bioavailability is low, on the order of 30-50%. Thus, considerably higher amounts of drug are delivered to the patient when the drug is administered intravenously compared to oral administration of an identical dose. Digoxin demonstrates highly variable bioavailability, depending upon a variety of factors including the preparation used and concomitant drug therapy. This problem can be partially circumvented with newer preparations such as a gel encapsulated form, which is consistently well absorbed with reproducible plasma concentrations. In some situations, a reduction in the rate of gastrointestinal absorption can be beneficial during drug therapy. For both mexiletine and tocainide, concomitant administration of food at the time of dosing reduces peak plasma concentrations due to diminished absorption, with a lower incidence of concentration-related side effects. Bioavailability is low for some drugs due to pre-systemic clearance, or first-pass metabolism, in the liver or intestine. An example is verapamil, for which a considerably higher dose must be administered orally to achieve the same plasma concentration following an intravenous dosage. Coadministration of an agent that inhibits first-pass metabolism (e.g., the CYP3A4 inhibitor grapefruit juice) can increase plasma concentrations and potentiate the effects of drugs such as verapamil which are metabolized by this route.
Distribution
Elimination of an intravenously-administered drug such as lidocaine is often a two-component process, with an initial fall in plasma concentration that reflects drug distribution. The theoretical body compartment into which drug diffuses is termed the total volume of distribution. It reflects both central and peripheral delivery, as well as protein/tissue binding. For drugs with rapid distribution (lidocaine) or slow onset of action (amiodarone), a loading dose is necessary to achieve prompt therapeutic effect. It is the volume of distribution that determines the size of loading dose required. In the case of lidocaine, it is essential to remember that the volume of distribution is smaller in the setting of congestive heart failure, necessitating a reduction of approximately 50% in the usual loading dose to avoid toxicity.
Metabolism
It is now well recognized that the cytochrome P450 system is a superfamily of multiple different enzymes. Expression or function of an individual enzyme can vary genetically and as a function of concomitant drug therapy. The impact of variable enzyme activity is greater if a given drug is degraded through a single metabolic pathway, as opposed to multiple routes of metabolism. The antiarrhythmic drug propafenone is metabolized by the CYP2D6 enzyme to an active metabolite, 5-hydroxy propafenone. The parent compound has mild β-adrenergic receptor blocking activity, which is essentially absent in the metabolite. Approximately 7 to 10% of Caucasians lack CYP2D6 and are therefore "poor metabolizers" of propafenone. These individuals develop higher plasma concentrations of the parent compound, with an increased likelihood of clinically-relevant β blockade and other untoward side effects. A number of drugs inhibit CYP2D6, including quinidine, the serotonin reuptake inhibitors such as fluoxetine, and tricyclic antidepressents. Concomitant therapy with these drugs essentially converts extensive metabolizers into poor metabolizers, with a similar risk of adverse events. While flecainide is metabolized by this enzyme, it is also eliminated by renal excretion. In the presence of renal insufficiency, individuals who lack CYP2D6 can achieve high plasma concentrations of flecainide, with an increased risk of potentially lethal toxicity.
Typically the most abundant CYP enzyme in humans is CYP3A4, which biotransforms many drugs, at least in part, by oxidation. Terfenadine is a compound that prolongs the cardiac action potential, and therefore the QT interval, by blocking the rapid component of the cardiac delayed rectifier, I Kr . It is normally metabolized to an acid metabolite which possesses antihistaminic activity but is electrophysiologically inactive. This metabolic process is mediated primarily by CYP3A4. The activity of this enzyme is reduced by concomitant therapy with a number of drugs, including macrolide antibiotics such as erythromycin and clarithromycin, azole antifungal agents such as ketoconazole and itraconazole, HIV protease inhibitors, and grapefruit juice. With inhibition of CYP3A4, plasma concentrations of terfenadine can be elevated, associated with marked QT prolongation and Torsades de Pointes. A similar mechanism of toxicity can occur with other antihistamines such as astemizole, as well as the gastrointestinal prokinetic drug cisapride. Due to the risk of cardiac toxicity, terfenadine, astemizole and cisapride have been removed from the US market and the active metabolite of terfenadine, fexofenadine, has been developed and marketed. Other clinically important consequences that can occur when CYP3A4 inhibitors are co-administered include an increased risk of rhabdomyolysis in patients receiving certain HMG-CoA reductase inhibitors (particularly lovastatin and simvastatin), and symptomatic hypotension in patients taking either dihydropyridine calcium channel blockers such as nifedipine, or the cGMP-specific phosphodiesterase inhibitor sildenafil, which is used to treat erectile dysfunction. Beneficial effects that can result from coadministration of CYP3A4 inhibitors include use of lower doses of cyclosporine to achieve therapeutic plasma concentrations, which reduces the cost of immunosuppressive therapy, and enhanced plasma concentrations of protease inhibitors (some of which are both substrates and inhibitors of CYP3A4) to improve drug efficacy in treating HIV infection.
Some antiarrhythmic drugs themselves can cause important drug interactions due to effects on metabolism of other compounds. For example as discussed above, quinidine inhibits the activity of CYP2D6, and coadministration of this compound can increase plasma concentrations of substrates such as propafenone. On the other hand, therapy with amiodarone (which inhibits CYP3A4 and probably other drug metabolizing enzymes) can cause a rise in plasma concentrations of
